Table 1.

% Growth inhibition of compounds 5c, 5d and 5f.

Panel/Cell Line	% Growth inhibition			Panel/Cell Line	% Growth inhibition
	Compound				Compound
	5c	5d	5f		5c	5d	5f
Leukemia				Melanoma
CCRF-CEM	40.64	−0.22	20.48	LOX IMVI	25.61	5.8	10.87
HL-60 (TB)	29.58	1.34	38.21	MALME-3M	4.81	−4.03	5.73
K-562	32.42	7.18	50.66	M14	40.08	7.13	24.61
MOLT-4	38.9	11.42	34.78	MDA-MB-435	24.92	5.38	22.95
RPMI-8226	48.96	19.75	44.48	SK-MEL-2	10.03	−6.35	0.73
SR	11.28	1.58	39.13	SK-MEL-28	8.57	−10.44	5.82
Non-Small Cell Lung Cancer				SK-MEL-5	29.89	1.76	31.01
A549/ATCC	39.14	11.24	45.14	UACC-257	2.92	1.42	30.59
EKVX	45.94	17.74	13.24	UACC-62	33.69	15.86	28.42
HOP-92	29.11	15.01	2.89	Ovarian Cancer
HOP-92	21.85	17.02	16.19	IGROV1	19	−5.64	1.44
NCI-H226	37.29	1.65	15.64	OVCAR-3	—	1.23	18.03
NCI-H23	21.39	5.79	6.86	OVCAR-4	28.3	6.36	21.38
NCI-H322M	15.54	8.05	−0.13	OVCAR-5	15.26	−0.62	7.95
NCI-H460	22.73	−6.31	38.84	OVCAR-8	20.76	6.85	37.13
NCI-H522	43.07	40.92	4.23	NCI/ADR-RES	19.47	−3.89	5.59
Colon Cancer				SK-OV-3	18.61	11.82	1.64
COLO 205	6.67	−14.94	28.99	Renal Cancer
HCC-2998	6.4	−9.24	14.04	786-0	25.18	2.86	12.87
HCT-116	48.8	5.9	48.64	A498	15.07	15.4	16.67
HCT-15	38.9	18.27	31.67	ACHN	72.83	4.67	6.49
HT29	31.43	17.77	63.81	CAKI-1	———	———	———
KM12	———	−1.93	32.87	RXF 393	28.4	−2.11	25.4
SW-620	2.92	−11.86	21.43	SN12C	11.57	3.69	31.97
CNS Cancer				TK-10	3.2	−12.49	10.36
SF-268	————	5.69	8.88	UO-31	54.99	38.03	61.91
SF-295	33.22	11.51	34.62	Breast Cancer
SF-539	11.92	2.56	0.75	MCF7	57.57	32.37	70.28
SNB-19	5.7	0.31	22.56	MDA-MB-231	25.7	10.27	11.47
SNB-75	34.78	29.2	9.78	HS 578T	20.95	4.66	21.21
U251	27.74	0.31	37.8	BT-549	27.92	17.36	22.29
Prostate Cancer				T-47D	55.67	33.16	51.28
PC-3	52.88	19.04	77.28	MDA-MB-468	30.96	−3	12.66
DU-31	————	−3.61	13.84